Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBP-0276 SAD/MAD and Food-effect Study in Healthy Subjects
NCT07708831Phase 1Completed
- Sponsor
- Clarent Biopharma Inc
- Start
- Sep 2025
- Primary completion
- Feb 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CBP-0276 (8 arms), sponsored by Clarent Biopharma Inc. Primary endpoints: Incidence of adverse events at 15 days, Severity of adverse events at 15 days and 4 more. Started Sep 2025; status: completed.
02
Drugs
CBP-0276
Beyond the preview
Go deeper on NCT07708831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07708831.